首页 | 本学科首页   官方微博 | 高级检索  
     

进展期食管癌患者接受紫杉醇联合顺铂新辅助化疗后的肿瘤标志物及癌基因评价
引用本文:雷秀兵,张彪,陈力. 进展期食管癌患者接受紫杉醇联合顺铂新辅助化疗后的肿瘤标志物及癌基因评价[J]. 临床和实验医学杂志, 2021, 20(2): 147-150
作者姓名:雷秀兵  张彪  陈力
作者单位:重庆市巴南区人民医院 肿瘤科 重庆 401320;重庆市巴南区人民医院 急诊科 重庆 401320
基金项目:国家自然科学基金(编号:30872464)。
摘    要:目的 研究紫杉醇联合顺铂新辅助化疗对进展期食管癌患者肿瘤标志物分泌及癌基因表达的影响.方法 前瞻性选择2017年3月至2020年1月期间重庆市巴南区人民医院收治的50例进展期食管癌患者,随机数字表法分为紫杉醇联合顺铂新辅助化疗+根治性手术的观察组、直接接受根治性手术的对照组,每组各25例.确诊时及手术前,测定2组患者血...

关 键 词:进展期食管癌  新辅助化疗  肿瘤标志物  癌基因

Evaluation of tumor markers and oncogenes in advanced esophageal cancer patients after neoadjuvant chemotherapy with paclitaxel and cisplatin
LEI Xiu-bing,ZHANG Biao,Chen-Li. Evaluation of tumor markers and oncogenes in advanced esophageal cancer patients after neoadjuvant chemotherapy with paclitaxel and cisplatin[J]. Journal of Clinical and Experimental Medicine, 2021, 20(2): 147-150
Authors:LEI Xiu-bing  ZHANG Biao  Chen-Li
Affiliation:(Department of Oncology,Chongqing Banan District People's Hospital,Chongqing 401320,China;Department of Emergency,Chongqing Banan District People's Hospital,Chongqing 401320,China)
Abstract:Objective To study the effect of neoadjuvant chemotherapy with paclitaxel and cisplatin on tumor marker secretion and oncogene expression in patients with advanced esophageal cancer.Methods Fifty patients with advanced esophageal cancer admitted in Chongqing Banan District People's Hospital from March 2017 to January 2020 were randomly divided into two groups:the observation group treated with paclitaxel combined with cisplatin neoadjuvant chemotherapy+radical operation and the control group treated with radical operation.The levels of serum tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9),squamous cell carcinoma antigen(SCC-Ag)and tumor-associated cytokeratin 19 fragment(CYFRA21-1)]were measured at the time of diagnosis and before surgery,and the expression of oncogenes in esophageal cancer lesions[DACH1 gene,esophageal cancer-related gene 4(ECRG4),Ras-related region family 1A(RASSF1A),phosphatase and tensin homologous genes deleted on chromosome 10(PTEN),cyclin D1(CCND1),vascular endothelial growth factor(VEGF),β-catenin(β-catenin)]was measured after surgery.Results Before surgery,the serum levels of CEA,CA19-9,SCC-Ag,and CYFRA21-1 in the observation group were(8.58±1.03)μg/L,(31.75±5.57)U/mL,(0.72±0.09)μg/L,(2.88±0.42)μg/L,which were significantly lower than those of the control group[(18.91±2.44)μg/L,(98.88±11.83)U/mL,(1.38±0.15)μg/L,(4.05±0.64)μg/L],the differences were statistically significant(P<0.05).After surgery,the mRNA expression levels of DACH1 gene,ECRG4,RASSF1A,and PTEN in the esophageal cancer lesions of the observation group were 0.97±0.14,1.03±0.16,1.01±0.16,0.96±0.09,which were significantly higher than those of the control group(0.57±0.08,0.44±0.07,0.61±0.08,0.66±0.08),CCND1,VEGF,β-catenin,Notch1 gene mRNA expression level were 0.62±0.08,0.53±0.07,0.65±0.08,0.58±0.07,which were significantly lower than those of the control group(1.06±0.18,1.01±0.14,1.02±0.17,0.99±0.12),the differences were statistically significant(P<0.05).Conclusion Neoadjuvant chemotherapy with paclitaxel and cisplatin can reduce tumor marker secretion and regulate oncogene expression in advanced esophageal cancer patients.
Keywords:Advanced esophageal cancer  Neoadjuvant chemotherapy  Tumor marker  Oncogene
本文献已被 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号